USMJ PAOG Confirms CBD Pharmaceutical And Nutra
Post# of 103059
(Total Views: 81)
Posted On: 02/09/2021 12:43:16 PM
USMJ
PAOG Confirms CBD Pharmaceutical And Nutraceutical Product Development Presentation Schedule
PR Newswire
SANDUSKY, Ohio, Feb. 9, 2021
SANDUSKY, Ohio, Feb. 9, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today confirmed plans to publish a multimedia presentation next week on the company's strategy to expand its nutraceutical product reach. The company added today that the presentation will also include details on the company's ongoing CBD pharmaceutical developments.
The company recently announced plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
The presentation is scheduled to be published next week on Tuesday, Feb 16th.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
In addition to PAOG's ongoing efforts to develop a pharmaceutical treatment for COPD, the company has announced engaging with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
Last Thursday, PAOG revealed for the first time a broader nutraceutical development initiative with plans to produce nutraceuticals for additional applications. The CBD nutraceutical market was valued at $3.8 billion in 2018 forecasted to grow at CAGR of over 18%.
PAOG plans to establish a revenue stream this year from its nutraceuticals' initiative adding to its recently confirmed a $300,000 sales agreement executed by the company's cannabis cultivation subsidiary. PAOG anticipates approximately $50,000 in revenue per quarter for six quarters starting with an estimated $50,000 in revenue expected to be reported for Q4 2020.
Last summer, PAOG acquired a cannabis cultivation business from Puration, Inc. (USOTC: PURA). The acquisition was made in conjunction with PAOG's overall strategy to refresh and renew its overall cannabis healthcare industry strategy.
PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
PAOG Confirms CBD Pharmaceutical And Nutraceutical Product Development Presentation Schedule
PR Newswire
SANDUSKY, Ohio, Feb. 9, 2021
SANDUSKY, Ohio, Feb. 9, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today confirmed plans to publish a multimedia presentation next week on the company's strategy to expand its nutraceutical product reach. The company added today that the presentation will also include details on the company's ongoing CBD pharmaceutical developments.
The company recently announced plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
The presentation is scheduled to be published next week on Tuesday, Feb 16th.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
In addition to PAOG's ongoing efforts to develop a pharmaceutical treatment for COPD, the company has announced engaging with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
Last Thursday, PAOG revealed for the first time a broader nutraceutical development initiative with plans to produce nutraceuticals for additional applications. The CBD nutraceutical market was valued at $3.8 billion in 2018 forecasted to grow at CAGR of over 18%.
PAOG plans to establish a revenue stream this year from its nutraceuticals' initiative adding to its recently confirmed a $300,000 sales agreement executed by the company's cannabis cultivation subsidiary. PAOG anticipates approximately $50,000 in revenue per quarter for six quarters starting with an estimated $50,000 in revenue expected to be reported for Q4 2020.
Last summer, PAOG acquired a cannabis cultivation business from Puration, Inc. (USOTC: PURA). The acquisition was made in conjunction with PAOG's overall strategy to refresh and renew its overall cannabis healthcare industry strategy.
PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
(0)
(0)Scroll down for more posts ▼